Am. J. Respir. Crit. Care Med., Volume 160, Number 3, September 1999, 829-834

Ribavirin in Ventilated Respiratory Syncytial Virus Bronchiolitis
A Randomized, Placebo-controlled Trial

ANNE-MARIE GUERGUERIAN, MARIE GAUTHIER, MARC H. LEBEL, CATHERINE ANN FARRELL, and JACQUES LACROIX

Pediatric Intensive Care Unit and Division of Infectious Diseases, Department of Pediatrics, Sainte-Justine Hospital, Université de Montréal, Montreal, Quebec, Canada

We undertook a prospective, double-blind, placebo-controlled trial to resolve the question of the clinical effectiveness of ribavirin in previously well infants who require ventilation for respiratory distress secondary to respiratory syncytial virus (RSV) bronchiolitis. Aerosol ribavirin or NaCl 0.9% was administered within 24 h of initiation of ventilation, 18 h/d, for a maximum of 7 d or until extubation. From March 1994 to March 1997, 42 children were randomized and 41 patients were retained for analysis. Baseline characteristics of each groupribavirin and placebo (20:21)were not significantly different with respect to age (62.5 ± 35.9 versus 62.7 ± 30.9 d), sex, weight, and length of ventilation pre-aerosol. "Intent to treat" outcome analysis found no significant differences in the length of the following: ventilation (102.16 ± 65.26 versus 126.28 ± 78.72 h; p = 0.29), aerosol therapy, stay in the intensive care unit, total oxygen therapy, and hospitalization. The aerosols were well tolerated and no deaths occurred. This trial demonstrates the lack of effectiveness of aerosolized ribavirin in reducing the length of ventilation and course of illness in infants with no underlying illness ventilated for respiratory distress secondary to RSV bronchiolitis.

This article has been cited by other articles:

				Subcommittee on Diagnosis and Management of Bronch Diagnosis and Management of Bronchiolitis Pediatrics, October 1, 2006; 118(4): 1774 - 1793. [Abstract] [Full Text] [PDF]

				V. J. King, M. Viswanathan, W. C. Bordley, A. M. Jackman, S. F. Sutton, K. N. Lohr, and T. S. Carey Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review Arch Pediatr Adolesc Med, February 1, 2004; 158(2): 127 - 137. [Abstract] [Full Text] [PDF]

				K. A. Keith, M. J. M. Hitchcock, W. A. Lee, A. Holy, and E. R. Kern Evaluation of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopoxvirus Replication Antimicrob. Agents Chemother., July 1, 2003; 47(7): 2193 - 2198. [Abstract] [Full Text] [PDF]

				A. G. Randolph, K. L. Meert, M. E. O'Neil, J. H. Hanson, P. M. Luckett, J. H. Arnold, R. G. Gedeit, P. N. Cox, J. S. Roberts, S. T. Venkataraman, et al. The Feasibility of Conducting Clinical Trials in Infants and Children with Acute Respiratory Failure Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1334 - 1340. [Abstract] [Full Text] [PDF]

				A. Mandelberg, G. Tal, M. Witzling, E. Someck, S. Houri, A. Balin, and I. E. Priel Nebulized 3% Hypertonic Saline Solution Treatment in Hospitalized Infants With Viral Bronchiolitis Chest, February 1, 2003; 123(2): 481 - 487. [Abstract] [Full Text] [PDF]

				E. M. Sarrell, G. Tal, M. Witzling, E. Someck, S. Houri, H. A. Cohen, and A. Mandelberg Nebulized 3% Hypertonic Saline Solution Treatment in Ambulatory Children With Viral Bronchiolitis Decreases Symptoms Chest, December 1, 2002; 122(6): 2015 - 2020. [Abstract] [Full Text] [PDF]

				S. Z. Nasr, P. J. Strouse, E. Soskolne, N. J. Maxvold, K. A. Garver, B. K. Rubin, and F. W. Moler Efficacy of Recombinant Human Deoxyribonuclease I in the Hospital Management of Respiratory Syncytial Virus Bronchiolitis Chest, July 1, 2001; 120(1): 203 - 208. [Abstract] [Full Text] [PDF]

				V. Khoshoo, D. Edell, and A.-M. GUERGUERIAN RIBAVARIN IN VENTILATED RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 333 - 334. [Full Text]